Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan

Chien Chih Chang, Mei Hwei Chang, Tzou-Yien Lin, Hong Chang Lee, Wu Shiun Hsieh, Ping Ing Lee

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background/Purpose: Rotavirus infection is the most common etiology of acute gastroenteritis in young children worldwide. The first rotavirus vaccine was licensed by the United States Food and Drug Administration in 1998 but was suspended soon after in 1999 because of the possibility of induced intussusception. This study evaluated the safety and immunogenicity of a newly developed pentavalent rotavirus vaccine in Taiwanese children. Methods: This was a phase III global trial designed to evaluate the safety and immunogenicity of an oral, live pentavalent rotavirus vaccine (RotaTeq™). Taiwan was the only site in Asia enrolled in this trial. Normal healthy infants aged 6-12 weeks were enrolled, and each of the subjects received either three oral doses of the vaccine or placebo solution. The safety of the vaccine, particularly the risk of intussusception, and immunogenicity were studied. Results: A total of 189 infants were enrolled. No increased risk of intussusception or other adverse reactions were noted following the vaccination. RotaTeq™ was immunogenic among subjects enrolled in Taiwan. At least a three-fold rise in serum antirotavirus IgA antibody was found among 93% of the vaccine group. The immunogenicity of RotaTeq™ in Taiwan was comparable to that in other areas. Conclusion: The pentavalent human-bovine vaccine, RotaTeq™, was safe, generally well-tolerated, and immunogenic among Taiwanese infants.

Original languageEnglish
Pages (from-to)280-285
Number of pages6
JournalJournal of the Formosan Medical Association
Volume108
Issue number4
DOIs
Publication statusPublished - Jan 1 2009
Externally publishedYes

Fingerprint

Rotavirus Vaccines
Taiwan
Intussusception
Vaccines
Safety
Rotavirus Infections
Gastroenteritis
United States Food and Drug Administration
Immunoglobulin A
Vaccination
Placebos
RotaTeq
Antibodies
Serum

Keywords

  • RotaTeq
  • Rotavirus
  • Rotavirus vaccines
  • Taiwan

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. / Chang, Chien Chih; Chang, Mei Hwei; Lin, Tzou-Yien; Lee, Hong Chang; Hsieh, Wu Shiun; Lee, Ping Ing.

In: Journal of the Formosan Medical Association, Vol. 108, No. 4, 01.01.2009, p. 280-285.

Research output: Contribution to journalArticle

Chang, Chien Chih ; Chang, Mei Hwei ; Lin, Tzou-Yien ; Lee, Hong Chang ; Hsieh, Wu Shiun ; Lee, Ping Ing. / Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. In: Journal of the Formosan Medical Association. 2009 ; Vol. 108, No. 4. pp. 280-285.
@article{376d7ff528ee442cb7229dbdc3bb216d,
title = "Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan",
abstract = "Background/Purpose: Rotavirus infection is the most common etiology of acute gastroenteritis in young children worldwide. The first rotavirus vaccine was licensed by the United States Food and Drug Administration in 1998 but was suspended soon after in 1999 because of the possibility of induced intussusception. This study evaluated the safety and immunogenicity of a newly developed pentavalent rotavirus vaccine in Taiwanese children. Methods: This was a phase III global trial designed to evaluate the safety and immunogenicity of an oral, live pentavalent rotavirus vaccine (RotaTeq™). Taiwan was the only site in Asia enrolled in this trial. Normal healthy infants aged 6-12 weeks were enrolled, and each of the subjects received either three oral doses of the vaccine or placebo solution. The safety of the vaccine, particularly the risk of intussusception, and immunogenicity were studied. Results: A total of 189 infants were enrolled. No increased risk of intussusception or other adverse reactions were noted following the vaccination. RotaTeq™ was immunogenic among subjects enrolled in Taiwan. At least a three-fold rise in serum antirotavirus IgA antibody was found among 93{\%} of the vaccine group. The immunogenicity of RotaTeq™ in Taiwan was comparable to that in other areas. Conclusion: The pentavalent human-bovine vaccine, RotaTeq™, was safe, generally well-tolerated, and immunogenic among Taiwanese infants.",
keywords = "RotaTeq, Rotavirus, Rotavirus vaccines, Taiwan",
author = "Chang, {Chien Chih} and Chang, {Mei Hwei} and Tzou-Yien Lin and Lee, {Hong Chang} and Hsieh, {Wu Shiun} and Lee, {Ping Ing}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/S0929-6646(09)60067-X",
language = "English",
volume = "108",
pages = "280--285",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan

AU - Chang, Chien Chih

AU - Chang, Mei Hwei

AU - Lin, Tzou-Yien

AU - Lee, Hong Chang

AU - Hsieh, Wu Shiun

AU - Lee, Ping Ing

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background/Purpose: Rotavirus infection is the most common etiology of acute gastroenteritis in young children worldwide. The first rotavirus vaccine was licensed by the United States Food and Drug Administration in 1998 but was suspended soon after in 1999 because of the possibility of induced intussusception. This study evaluated the safety and immunogenicity of a newly developed pentavalent rotavirus vaccine in Taiwanese children. Methods: This was a phase III global trial designed to evaluate the safety and immunogenicity of an oral, live pentavalent rotavirus vaccine (RotaTeq™). Taiwan was the only site in Asia enrolled in this trial. Normal healthy infants aged 6-12 weeks were enrolled, and each of the subjects received either three oral doses of the vaccine or placebo solution. The safety of the vaccine, particularly the risk of intussusception, and immunogenicity were studied. Results: A total of 189 infants were enrolled. No increased risk of intussusception or other adverse reactions were noted following the vaccination. RotaTeq™ was immunogenic among subjects enrolled in Taiwan. At least a three-fold rise in serum antirotavirus IgA antibody was found among 93% of the vaccine group. The immunogenicity of RotaTeq™ in Taiwan was comparable to that in other areas. Conclusion: The pentavalent human-bovine vaccine, RotaTeq™, was safe, generally well-tolerated, and immunogenic among Taiwanese infants.

AB - Background/Purpose: Rotavirus infection is the most common etiology of acute gastroenteritis in young children worldwide. The first rotavirus vaccine was licensed by the United States Food and Drug Administration in 1998 but was suspended soon after in 1999 because of the possibility of induced intussusception. This study evaluated the safety and immunogenicity of a newly developed pentavalent rotavirus vaccine in Taiwanese children. Methods: This was a phase III global trial designed to evaluate the safety and immunogenicity of an oral, live pentavalent rotavirus vaccine (RotaTeq™). Taiwan was the only site in Asia enrolled in this trial. Normal healthy infants aged 6-12 weeks were enrolled, and each of the subjects received either three oral doses of the vaccine or placebo solution. The safety of the vaccine, particularly the risk of intussusception, and immunogenicity were studied. Results: A total of 189 infants were enrolled. No increased risk of intussusception or other adverse reactions were noted following the vaccination. RotaTeq™ was immunogenic among subjects enrolled in Taiwan. At least a three-fold rise in serum antirotavirus IgA antibody was found among 93% of the vaccine group. The immunogenicity of RotaTeq™ in Taiwan was comparable to that in other areas. Conclusion: The pentavalent human-bovine vaccine, RotaTeq™, was safe, generally well-tolerated, and immunogenic among Taiwanese infants.

KW - RotaTeq

KW - Rotavirus

KW - Rotavirus vaccines

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=65549107836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549107836&partnerID=8YFLogxK

U2 - 10.1016/S0929-6646(09)60067-X

DO - 10.1016/S0929-6646(09)60067-X

M3 - Article

C2 - 19369174

AN - SCOPUS:65549107836

VL - 108

SP - 280

EP - 285

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 4

ER -